Reviva Pharmaceuticals (NASDAQ:RVPH) Earns Buy Rating from Analysts at Roth Mkm

Stock analysts at Roth Mkm began coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research note issued on Friday,Benzinga reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Roth Mkm’s target price indicates a potential upside of 274.33% from the stock’s previous close.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Reviva Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $12.67.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $1.87 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $5.14. The firm’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.28. The firm has a market cap of $62.53 million, a price-to-earnings ratio of -1.68 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.